Efficacy Analysis of Lamivudine Combined with Thymosin α1 in Treatment of Chronic Hepatitis B

Objective To evaluate the efficacy of Lamivudine alone or combined with Thymosin α1 in treatment of chronic hepatitis B(CHB).Methods The 52 patients with CHB were randomly divided into combination therapy group(26 cases)and Lamivudine group(26 cases).The combination therapy group was treated with Lamivudine,100 mg/d,orally,for 18 months,and Combining Thymosin α1,1.6 mg,two times each week,subcutaneously,for 6 mouths.Lamivudine group was treated with lamivudine,100 mg/d,orally,for 18 months.Results After 12 and 18 months of treatment,there were significant differences in the rate of serum HBV DNA turned to negative,HBeAg/anti-HBe sero-conversion rate and ALT recovery rate between combination therapy group and Lamivudine group(P0.05).Conclusion The combination of Lamivudine and Thymosin α1 has better effect than the monotherapy of Lamivudine in patients with CHB.